PD-1 Blockade with Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma: A Multicenter, Single-Arm, Phase 2 Study

  • 1.
    • Caesarman E
    • Damania B
    • Krown SE
    • Martin J.
    • Bower M
    • Whitby D

    Kaposi’s sarcoma.

    Nat Rev Dis Primers. 2019; 5: 9

    See in the article
    • Google Scholar
  • 2.
    • Dupuy S
    • Lambert M
    • Zucman D
    • et al.

    Human herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during asymptomatic infection and Kaposi’s sarcoma.

    PLoS Pathog. 2012; 8e1002486

    See in the article
    • Google Scholar
  • 3.
    • Lebbe C
    • Garbe C
    • Stratigos AJ
    • et al.

    Diagnosis and treatment of Kaposi’s sarcoma: European consensus interdisciplinary guide (EDF/EADO/EORTC).

    Eur J Cancer. 2019; 114: 117-127

    See in the article
    • Google Scholar
  • 4.
    • Regnier-Rosencher E
    • Guillot B
    • Dupin N.

    Treatments for classic Kaposi’s sarcoma: a systematic review of the literature.

    J Am Acad Dermatol. 2013; 68: 313-331

    See in the article
    • Google Scholar
  • 5.
    • Cianfrocca M
    • Lee S
    • Von Roenn J.
    • et al.

    Randomized trial comparing paclitaxel with pegylated liposomal doxorubicin for advanced Kaposi’s sarcoma associated with human immunodeficiency virus: evidence for palliation of symptoms with chemotherapy.

    Cancer. 2010; 116: 3969-3977

    See in the article
    • Google Scholar
  • 6.
    • Polizotto MN
    • Uldrick TS
    • Wyvill KM
    • et al.

    Pomalidomide for symptomatic Kaposi’s sarcoma in HIV-infected and uninfected people: a phase I/II study.

    J Clin Oncol. 2016; 34: 4125-4131

    See in the article
    • Google Scholar
  • 7.
    • Klémen ND
    • Hwang S
    • Bradic M
    • et al.

    Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced sarcoma.

    Clin Cancer Res. 2021; 135244

    See in the article
    • Google Scholar
  • 8.
    • Nghiem PT
    • Bhatia S
    • EJ Lipson
    • et al.

    PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma.

    N Engl J Med. 2016; 374: 2542-2552

    See in the article
    • Google Scholar
  • 9.
    • Yarchoan M
    • Hopkins A.
    • Jaffee EM

    Tumor mutational load and response rate to PD-1 inhibition.

    N Engl J Med. 2017; 377: 2500-2501

    See in the article
    • Google Scholar
  • ten.
    • Beldi-Ferchiou A
    • Lambert M
    • Dogniaux S
    • et al.

    PD-1 mediates the functional depletion of activated NK cells in patients with Kaposi’s sarcoma.

    Oncocible. 2016; 7: 72961-72977

    See in the article
    • Google Scholar
  • 11.
    • Delyon J
    • Bizot A
    • Battistelle M
    • Magdalene I
    • Vercellin L
    • Lebbe C

    PD-1 blockade with nivolumab in endemic Kaposi’s sarcoma.

    Anne Oncol. 2018; 29: 1067-1069

    See in the article
    • Google Scholar
  • 12.
    • Saller J.
    • Walko CM
    • Millis SZ
    • Henderson-Jackson E
    • Makanji R
    • Brohl AS

    Response to checkpoint inhibitor treatment in advanced classic Kaposi’s sarcoma: about a case and immunogenomic study.

    J Natl Compr Canc Netw. 2018; 16: 797-800

    See in the article
    • Google Scholar
  • 13.
    • Tabata MM
    • Novoa RA
    • BUI NQ
    • Zaba LC

    Successful treatment of HIV-negative Kaposi’s sarcoma with ipilimumab and nivolumab and concurrent management of psoriasis and baseline bullous pemphigoid.

    JAAD Case Rep. 2020; 6: 447-449

    See in the article
    • Google Scholar
  • 14.
    • Cesmeci E
    • Guven DC
    • Aktas BY
    • Aksoy S

    Case of metastatic Kaposi’s sarcoma successfully treated with anti-PD-1 immunotherapy.

    J Oncol Pharm Pract. 2021; 27: 1766-1769

    See in the article
    • Google Scholar
  • 15.
    • Uldrick TS
    • Gonçalves PH
    • Abdul Hay M.
    • et al.

    Safety evaluation of pembrolizumab in patients with HIV and advanced cancer – a phase 1 study.

    JAMA Oncol. 2019; 5: 1332-1339

    See in the article
    • Google Scholar
  • 16.
    • Rajdev L.
    • S-lens
    • Ramos JC
    • et al.

    1023MO AMC 095: A report on nivolumab (nivo) in advanced HIV-associated solid tumors (STs).

    Anne Oncol. 2020; 31: S706

    See in the article
    • Google Scholar
  • 17.
    • Delyon J
    • Layout D
    • Baroudjian B
    • Lebbe C

    Letter to the editor: Could the immunogenicity of Kaposi’s sarcoma be linked more to viral antigens than to tumor mutational burden?.

    J Natl Compr Canc Netw. 2018; 16: 1418-1419

    See in the article
    • Google Scholar
  • 18.
    • Brambilla L
    • Genoese floor
    • Berti E
    • et al.

    Diagnosis and treatment of classic and iatrogenic Kaposi’s sarcoma: Italian recommendations.

    Ital J Dermatol Venereol. 2021; 156: 356-365

    See in the article
    • Google Scholar
  • 19.
    • Benajiba L
    • Lambert J.
    • La Selva R
    • et al.

    Systemic therapeutic initiation in classic and endemic Kaposi’s sarcoma: risk factors and global multi-state modeling in a monocentric cohort study.

    Cancers (Basel). 2021; 132519

    See in the article
    • Google Scholar
  • 20.
    • Sobngwi E
    • Choukem SP
    • Agbalika F
    • et al.

    Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-Saharan Africans.

    JAMA. 2008; 299: 2770-2776

    See in the article
    • Google Scholar
  • 21.
    • Chowell D
    • Krishna C
    • Pierini F
    • et al.

    The evolutionary divergence of the HLA class I genotype has an impact on the efficacy of cancer immunotherapy.

    NatMed. 2019; 25: 1715-1720

    See in the article
    • Google Scholar
  • 22.
    • Pierini F
    • Lenz TL

    Advantage of the divergent allele at the level of human MHC genes: signatures of past and current selection.

    Mol Biol Evol. 2018; 35: 2145-2158

    See in the article
    • Google Scholar
  • 23.
    • Grantham R

    Amino acid difference formula to help explain protein evolution.

    Science. 1974; 185: 862-864

    See in the article
    • Google Scholar
  • 24.
    • Galanina N.
    • Goodman AM
    • RP Cohen
    • Frampton DG
    • Kurzrock R

    Successful treatment of HIV-associated Kaposi’s sarcoma with immune checkpoint blockade.

    Cancer Immunol Res. 2018; 6: 1129-1135

    See in the article
    • Google Scholar
  • 25.
    • Delyon J
    • Zuber J.
    • Dorent R
    • et al.

    Immune checkpoint inhibitors in transplantation – a case series and comprehensive review of current knowledge.

    Transplantation. 2021; 105: 67-78

    See in the article
    • Google Scholar
  • 26.
    • Gambichler T
    • Susok L

    PD-1 blockade for disseminated Kaposi’s sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia.

    Immunotherapy. 2020; 12: 451-457

    See in the article
    • Google Scholar
  • 27.
    • Di Lorenzo G.
    • Kreuter A
    • Di Trolio R
    • et al.

    Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of nonvisceral classic Kaposi’s sarcoma: a multicenter study.

    J Invest Dermatol. 2008; 128: 1578-1580

    See in the article
    • Google Scholar
  • 28.
    • Brambilla L
    • Romanelli A.
    • Bellinvia M
    • et al.

    Weekly paclitaxel for advanced classical aggressive Kaposi’s sarcoma: experience of 17 cases.

    Br J Dermatol. 2008; 158: 1339-1344

    See in the article
    • Google Scholar
  • 29.
    • Fardet L
    • Stoebner PE
    • Bachelez H
    • et al.

    Taxane treatment of refractory or life-threatening Kaposi’s sarcoma not associated with human immunodeficiency virus infection.

    Cancer. 2006; 106: 1785-1789

    See in the article
    • Google Scholar
  • 30.
    • Herbst RS
    • Baas P
    • Kim DW
    • et al.

    Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial.

    Lancet. 2016; 387: 1540-1550

    See in the article
    • Google Scholar
  • 31.
    • Anderson LA
    • Laurie C
    • Romano N.
    • et al.

    Risk factors for classic Kaposi’s sarcoma in a population-based case-control study in Sicily.

    Biomarkers of cancer epidemiol Prev. 2008; 17: 3435-3443

    See in the article
    • Google Scholar
  • 32.
    • Topalian SL
    • Hodi FS
    • Brahmer JR
    • et al.

    Safety, activity and immune correlates of anti-PD-1 antibodies in cancer.

    N Engl J Med. 2012; 366: 2443-2454

    See in the article
    • Google Scholar
  • 33.
    • Country S
    • Bagir EK
    • Become MA
    • Gonlusen G

    Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.

    Med Oncol. 2016; 33: 93

    See in the article
    • Google Scholar
  • 34.
    • Kim Y.J.
    • Jung C.J.
    • Won the CH
    • et al.

    Expression of PD-1 and PD-L1 in Kaposi’s sarcoma: a comparative study according to pathological stage and clinical characteristics.

    J Cutan Pathol. 2021; 48: 221-228

    See in the article
    • Google Scholar
  • 35.
    • Chen B.J.
    • Chapuy B
    • Ouyang J
    • et al.

    PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

    Clin Cancer Res. 2013; 19: 3462-3473

    See in the article
    • Google Scholar
  • 36.
    • Gambichler T
    • Koim S
    • Wrobel M
    • et al.

    Expression of programmed cell death proteins in Kaposi’s sarcoma and cutaneous angiosarcoma.

    J Immunother. 2020; 43: 169-174

    See in the article
    • Google Scholar
  • 37.
    • Genoese floor
    • Venegoni L
    • Fanoni D
    • Tourlaki A
    • Brambilla L
    • Berti E

    PD-L1 expression in the tumor microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi’s sarcoma.

    J Eur Acad Dermatol Venereol. 2019; 33: e269-e271

    See in the article
    • Google Scholar
  • 38.
    • Arora J
    • Pierini F
    • McLaren pajamas
    • Carrington M
    • Fellay J.
    • Lenz TL

    The advantage of HLA heterozygotes against HIV-1 is driven by quantitative and qualitative differences in the specific peptide presentation of HLA alleles.

    Mol Biol Evol. 2020; 37: 639-650

    See in the article
    • Google Scholar
  • 39.
    • Ramasvami R
    • Polizotto MN
    • Lurain K
    • et al.

    Safety, activity and long-term results of pomalidomide in the treatment of Kaposi’s sarcoma in people with and without HIV infection.

    Clin Cancer Res. 2022; (published online on January 19.)

    https://doi.org/10.1158/1078-0432.CCR-21-3364
    See in the article
    • Google Scholar
  • 40.
    • Jansen YJL
    • Rozeman EA
    • Mason R
    • et al.

    Discontinuation of anti-PD-1 antibody treatment in the absence of disease progression or treatment-limiting toxicity: clinical outcomes in advanced melanoma.

    Anne Oncol. 2019; 30: 1154-1161

    See in the article
    • Google Scholar

  • Source link